In addition to the key roles of androgens and AR in the regulation of prostate cancer pathogenesis, a variety of hormone-responsive GPCRs are also involved in the occurrence and development of prostate cancer, so they may serve as potential alternative drug targets for prostate cancer intervention. This evidence concerns the gene AR and prostate carcinoma.